Ask AI
EGFR Therapy AE Management

CE

Staying the Course: Pharmacist Best Practices for Managing Adverse Events and Maintaining Therapy in EGFR-Mutated NSCLC

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: May 28, 2026

Expiration: November 27, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with lung cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

After multidisciplinary review, the 73-yr-old patient with metastatic EGFR exon 21 L858R NSCLC starts first-line amivantamab plus lazertinib.

Which pharmacist-led management plan is most appropriate at treatment initiation to help sustain therapy adherence while minimizing toxicity?

4.

A patient with progressive EGFR-mutated NSCLC after osimertinib plus chemotherapy is preparing to start amivantamab plus lazertinib and asks what to expect if she were treated with subcutaneous (SC) amivantamab vs intravenous (IV) amivantamab.

Which counseling statement is most appropriate to support shared decision-making about treatment expectations?

5.

A patient with metastatic EGFR L858R NSCLC starts IV amivantamab plus lazertinib. At Wk 6, she reports new dyspnea.

Which action is most appropriate?

6.

Which treatment-emergent AE profile is most characteristic of datopotamab deruxtecan, a TROP2-directed ADC approved for patients with previously treated EGFR-mutated NSCLC?